Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BrainScope Completes Trials Of Brain Injury Assessment In Collaboration With US DOD, NFL, GE

Executive Summary

Investigators have completed the algorithm development and clinical validation studies of objective, electroencephalogram-based technology in adolescent and young adult populations, the company says. The studies were funded by a $9.9m research contract from the US Department of Defense, award funding from the National Football League-GE Head Health Challenge, and BrainScope.

You may also be interested in...



BrainScope’s Head Injury Assessment Device Moves Closer To Military, Sports Use

BrainScope received 510(k) clearance in May for Ahead 200, a second-generation, handheld, noninvasive device for the adjunctive assessment of traumatic brain injury in adults over 18 years of age. With an estimated 60 million cases of TBI annually worldwide, the company is initially focusing on military and sports applications, but is also looking at emerging markets such as India and China, where there are fewer CT scanners and the rate of head injury is substantially higher than in the US.

Lawyers Seek Clients For Possible Securities Fraud Case Against Dentsply Sirona

An internal investigation found that the company’s leadership may have directed employees to improperly account for sales-incentive payments. As a result, the company has been unable to file its quarterly report for the first quarter of 2022 with the SEC.

Vince Burgess Steps Down After Nine Years As Acutus CEO

Analysts believe the company’s arrythmia mapping technology could potentially disrupt the electrophysiology mapping market, but are disappointed with Acutus’ growth so far.

Topics

Related Companies

UsernamePublicRestriction

Register

MT124878

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel